• Akari Therapeutics filed a PCT patent application covering its PH1 ADC payload designed to disrupt RNA splicing in cancers.
• Filing targets claims on PH1’s ability to modulate alternative splicing across multiple tumor-driving pathways beyond its cytotoxic mechanism.
• Portfolio expansion supports Akari’s PH1-based ADC platform, positioned as a differentiated approach versus tubulin inhibitors or DNA-damaging payloads.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010825PRIMZONEFULLFEED9837828) on October 01, 2026, and is solely responsible for the information contained therein.